More articles from Article
- The Biological Sequelae of Stromal Cell-derived Factor-1α in Multiple Myeloma 1 This work was supported by Multiple Myeloma Research Foundation Senior Awards (to T. H. and D. C.), Leukemia and Lymphoma Society Scholar Award (to N. M.), NIH Grant PO-1 78378, and the Doris Duke Distinguished Clinical Research Scientist Award (to K. A.).1
- Interaction of the Novel Anthracycline Antitumor Agent N-Benzyladriamycin-14-valerate with the C1-Regulatory Domain of Protein Kinase C: Structural Requirements, Isoform Specificity, and Correlation with Drug Cytotoxicity 1 Supported by CA 44890 (to T. W. S.), CA 74197 (to M. G. K.), ACS RPG-97-092-01-CNE (to M. G. K.), NIH Medical Student Research Fellowship T35 DK07405-11 (to J. B. R.), and the Computational Research on Materials Institute at the University of Memphis.1
- Retinoic Acid-induced Growth Arrest and Differentiation: Retinoic Acid Up-Regulates CD32 (FcγRII) Expression, the Ectopic Expression of Which Retards the Cell Cycle 1 Supported in part by grants from the NIH (USPHS) and United States Department of Agriculture. J. W. and T. J. L. are recipients of National Institute of Environmental Health Sciences Training Fellowship ESO7052.1
- Systemic Tumor-targeted Gene Delivery by Anti-Transferrin Receptor scFv-Immunoliposomes 1 This work was supported in part by National Cancer Institute Grant R01 CA45158 (to E. C.), National Cancer Institute Small Business Technology Transfer Phase I Grant R41 CA80449 (to E. C.), and a grant from SynerGene Therapeutics, Inc.1
- Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated Extracellular- regulated Kinase (ERK) Pathway 1 This work was supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.1
- A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene 1 Supported by the Israel-University of Alabama at Birmingham Medical Exchange Fund (Y. S. H.) and by grants from the United States Department of Defense (DAMD17-00-1-0002 and DAMD17-98-1-8571), the National Cancer Institute (R01 CA83821, IT32 CA75930, and P50 CA83591), the Lustgarten Foundation (LF043), and the CaPCURE Foundation (to D. T. C.).1